novo nordisk glp-1 receptor agonists weight management diabetes treatments Wegovy for the Treatment of Chronic Management, US The Unstoppable Rise of GLP-1

de Heer, J., Rasmussen, C., Coy, D

Combined activation of both receptors may act synergistically providing additive effects on glucose and body weight in comparison of GLP1 analogues alone

As 2024 drew to a close, Englands NICE finalised its guidance for Mounjaro, recommending its use in the primary care setting, for treating adults with a body mass index (BMI) 35 kg/m2 and at least one weight-related co-morbidity, alongside a reduced-calorie diet and increased exercise, with no restriction on treatment duration, equating to a total eligible population of 3.4 million patients [5]

Dismiss this notification PatientsLikeMe would like to remind you that your browser is out of date and many features of the website may not function as expected

Glucagon-like peptide-1 receptor agonist treatment does not reduce abuse-related effects of opioid drugs

[DOI] [PubMed] [Google Scholar] 109.Bartholdy K.V., Johansen N.D., Skaarup K.G., Modin D., Landler N., Langhoff A.F., Ottosen C.:I., Espersen C., Dons M., Borchsenius J.I.M., et al